ログイン
言語:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

{"_buckets": {"deposit": "55d00170-8232-490f-a1f5-08f80e52d4ee"}, "_deposit": {"id": "23420", "owners": [], "pid": {"revision_id": 0, "type": "depid", "value": "23420"}, "status": "published"}, "_oai": {"id": "oai:nagoya.repo.nii.ac.jp:00023420", "sets": ["1949"]}, "item_9_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2017-02", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "1", "bibliographicPageEnd": "16", "bibliographicPageStart": "9", "bibliographicVolumeNumber": "79", "bibliographic_titles": [{"bibliographic_title": "Nagoya Journal of Medical Science"}]}]}, "item_9_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "This study investigated the effects of switching from combination therapy with either alogliptin (Alo) or pioglitazone (Pio) to fixed-dose combination therapy (FDCT) with alogliptin and pioglitazone (Alo-Pio FDCT). The usefulness and efficacy of Alo-Pio FDCT were investigated. A total of 50 outpatients with type 2 diabetes mellitus (T2DM) treated with Alo and 47 outpatients with T2DM treated with Pio were switched to Alo-Pio FDCT, and its efficacy and usefulness were evaluated. Significant improvements were observed in hemoglobinA1c (HbA1c), alanine transaminase (ALT), and γ-glutamyl transpeptidase (GGT) levels after switching to Alo-Pio FDCT for 16 weeks in both groups. Only the group switching from Alo to Alo-Pio FDCT showed significant improvements in high-density lipoprotein cholesterol (HDL) levels and triglyceride levels. In a multivariate logistic regression model of the variation in the change of HbA1c at 16 weeks, ALT and GGT were independent predictors of the change of HbA1c at 16 weeks. In addition, the switch to Alo-Pio FDCT improved glycemic control to a certain degree regardless of BMI. Switching from either Alo or Pio to Alo-PIO FDCT may, unlike monotherapy with a DPP-4 inhibitor, be effective for patients with T2DM regardless of whether they are obese or lean.", "subitem_description_type": "Abstract"}]}, "item_9_identifier_60": {"attribute_name": "URI", "attribute_value_mlt": [{"subitem_identifier_type": "URI", "subitem_identifier_uri": "http://www.med.nagoya-u.ac.jp/medlib/nagoya_j_med_sci/791.html"}, {"subitem_identifier_type": "HDL", "subitem_identifier_uri": "http://hdl.handle.net/2237/25616"}]}, "item_9_identifier_registration": {"attribute_name": "ID登録", "attribute_value_mlt": [{"subitem_identifier_reg_text": "10.18999/nagjms.79.1.9", "subitem_identifier_reg_type": "JaLC"}]}, "item_9_publisher_32": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Nagoya University Graduate School of Medicine, School of Medicine"}]}, "item_9_select_15": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_select_item": "publisher"}]}, "item_9_source_id_7": {"attribute_name": "ISSN(print)", "attribute_value_mlt": [{"subitem_source_identifier": "0027-7622", "subitem_source_identifier_type": "ISSN"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Aoki, Chie"}], "nameIdentifiers": [{"nameIdentifier": "69454", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Suzuki, Kunihiro"}], "nameIdentifiers": [{"nameIdentifier": "69455", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kuroda, Hisamoto"}], "nameIdentifiers": [{"nameIdentifier": "69456", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Sagara, Masaaki"}], "nameIdentifiers": [{"nameIdentifier": "69457", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Shimizu, Masanori"}], "nameIdentifiers": [{"nameIdentifier": "69458", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kasai, Kikuo"}], "nameIdentifiers": [{"nameIdentifier": "69459", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Aso, Yoshimasa"}], "nameIdentifiers": [{"nameIdentifier": "69460", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2018-02-22"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "11_Aoki.pdf", "filesize": [{"value": "266.5 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 266500.0, "url": {"label": "11_Aoki.pdf", "url": "https://nagoya.repo.nii.ac.jp/record/23420/files/11_Aoki.pdf"}, "version_id": "af844c6b-abd6-49b9-af73-820ccb01e11c"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "type 2 diabetes mellitus", "subitem_subject_scheme": "Other"}, {"subitem_subject": "fixed-dose combination therapy", "subitem_subject_scheme": "Other"}, {"subitem_subject": "pioglitazone", "subitem_subject_scheme": "Other"}, {"subitem_subject": "dipeptidyl peptidase-4 inhibitor", "subitem_subject_scheme": "Other"}, {"subitem_subject": "alogliptin", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "departmental bulletin paper", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Fixed-dose combination of alogliptin/pioglitazone improves glycemic control in Japanese patients with type 2 diabetes mellitus independent of body mass index", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Fixed-dose combination of alogliptin/pioglitazone improves glycemic control in Japanese patients with type 2 diabetes mellitus independent of body mass index"}]}, "item_type_id": "9", "owner": "1", "path": ["1949"], "permalink_uri": "https://doi.org/10.18999/nagjms.79.1.9", "pubdate": {"attribute_name": "公開日", "attribute_value": "2017-02-23"}, "publish_date": "2017-02-23", "publish_status": "0", "recid": "23420", "relation": {}, "relation_version_is_last": true, "title": ["Fixed-dose combination of alogliptin/pioglitazone improves glycemic control in Japanese patients with type 2 diabetes mellitus independent of body mass index"], "weko_shared_id": null}
  1. C100 医学部/医学系研究科
  2. C100b 紀要
  3. Nagoya journal of medical science
  4. 79(1)

Fixed-dose combination of alogliptin/pioglitazone improves glycemic control in Japanese patients with type 2 diabetes mellitus independent of body mass index

https://doi.org/10.18999/nagjms.79.1.9
https://doi.org/10.18999/nagjms.79.1.9
3a1a16f5-d643-4fc2-bae4-c3c9f1861340
名前 / ファイル ライセンス アクション
11_Aoki.pdf 11_Aoki.pdf (266.5 kB)
Item type 紀要論文 / Departmental Bulletin Paper(1)
公開日 2017-02-23
タイトル
タイトル Fixed-dose combination of alogliptin/pioglitazone improves glycemic control in Japanese patients with type 2 diabetes mellitus independent of body mass index
著者 Aoki, Chie

× Aoki, Chie

WEKO 69454

Aoki, Chie

Search repository
Suzuki, Kunihiro

× Suzuki, Kunihiro

WEKO 69455

Suzuki, Kunihiro

Search repository
Kuroda, Hisamoto

× Kuroda, Hisamoto

WEKO 69456

Kuroda, Hisamoto

Search repository
Sagara, Masaaki

× Sagara, Masaaki

WEKO 69457

Sagara, Masaaki

Search repository
Shimizu, Masanori

× Shimizu, Masanori

WEKO 69458

Shimizu, Masanori

Search repository
Kasai, Kikuo

× Kasai, Kikuo

WEKO 69459

Kasai, Kikuo

Search repository
Aso, Yoshimasa

× Aso, Yoshimasa

WEKO 69460

Aso, Yoshimasa

Search repository
キーワード
主題Scheme Other
主題 type 2 diabetes mellitus
キーワード
主題Scheme Other
主題 fixed-dose combination therapy
キーワード
主題Scheme Other
主題 pioglitazone
キーワード
主題Scheme Other
主題 dipeptidyl peptidase-4 inhibitor
キーワード
主題Scheme Other
主題 alogliptin
抄録
内容記述 This study investigated the effects of switching from combination therapy with either alogliptin (Alo) or pioglitazone (Pio) to fixed-dose combination therapy (FDCT) with alogliptin and pioglitazone (Alo-Pio FDCT). The usefulness and efficacy of Alo-Pio FDCT were investigated. A total of 50 outpatients with type 2 diabetes mellitus (T2DM) treated with Alo and 47 outpatients with T2DM treated with Pio were switched to Alo-Pio FDCT, and its efficacy and usefulness were evaluated. Significant improvements were observed in hemoglobinA1c (HbA1c), alanine transaminase (ALT), and γ-glutamyl transpeptidase (GGT) levels after switching to Alo-Pio FDCT for 16 weeks in both groups. Only the group switching from Alo to Alo-Pio FDCT showed significant improvements in high-density lipoprotein cholesterol (HDL) levels and triglyceride levels. In a multivariate logistic regression model of the variation in the change of HbA1c at 16 weeks, ALT and GGT were independent predictors of the change of HbA1c at 16 weeks. In addition, the switch to Alo-Pio FDCT improved glycemic control to a certain degree regardless of BMI. Switching from either Alo or Pio to Alo-PIO FDCT may, unlike monotherapy with a DPP-4 inhibitor, be effective for patients with T2DM regardless of whether they are obese or lean.
内容記述タイプ Abstract
出版者
出版者 Nagoya University Graduate School of Medicine, School of Medicine
言語
言語 eng
資源タイプ
資源 http://purl.org/coar/resource_type/c_6501
タイプ departmental bulletin paper
ID登録
ID登録 10.18999/nagjms.79.1.9
ID登録タイプ JaLC
ISSN(print)
収録物識別子タイプ ISSN
収録物識別子 0027-7622
書誌情報 Nagoya Journal of Medical Science

巻 79, 号 1, p. 9-16, 発行日 2017-02
著者版フラグ
値 publisher
URI
識別子 http://www.med.nagoya-u.ac.jp/medlib/nagoya_j_med_sci/791.html
識別子タイプ URI
URI
識別子 http://hdl.handle.net/2237/25616
識別子タイプ HDL
戻る
0
views
See details
Views

Versions

Ver.1 2021-03-01 14:35:22.038626
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by WEKO3


Powered by WEKO3